Company Overview and News
After a win in the Oct.-22 midterm elections, President Mauricio Macri unveiled reforms to trim a fiscal deficit seen ending 2017 at about 4% of gross domestic product. The result: Macri will spend less on a subsidy that natural gas drillers depended on for their shale projects. While new wells qualify, it’ll be tough for those in production to get the higher prices.
BUENOS AIRES, Sept 25 (Reuters) - The government of Argentina is planning to suspend a price-setting system for domestic fuel sales next month thanks to the recent rise in global oil prices, the country’s energy and mining minister said Monday.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BRASILIA (Reuters) - Brazilian prosecutors intend to open a formal investigation into last year's controversial sale of the Argentine subsidiary of Petrobras, Brazil's state-controlled oil company, a lawyer representing some Petrobras shareholders said on Wednesday.
Tulsa-based midstream player SemGroup Corporation (SEMG - Free Report) recently clinched a $2.1 billion deal to acquire Houston Fuel Oil Terminal Co from investment funds managed by Alinda Capital Partners. The agreement will advance Semgroup’s Gulf-Coast strategy. Notably, this is the biggest acquisition deal signed by the company to date. The deal will provide the company with ownership of one of the largest U.
Companhia Paranaense de Energia (ELP - Free Report) or COPEL reported impressive first-quarter 2017 results, with net income surging 206.6% year over year to R$417.3 million ($132.9 million). Earnings per share were R$1.50 or 48 cents per American Depository Receipt (ADR), up from R$0.49 per share or 13 cents per ADR. Revenues Net operating revenue in the quarter totaled R$3,297 million ($1,050 million), reflecting year-over-year growth of 7%.
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
*The Company’s yield based on dividends announced in the last 12 months as at the date of the release of this announcement is 3.6% and includes the 2016 final dividend of 4.00 cents per share declared on 22 November 2016 and paid to shareholders on 17 February 2017 and the 2016 interim dividend of 2.60 cents per share announced on 16 May 2016 and paid to shareholders on 1 July 2016.
CenterPoint Energy Inc. (CNP - Free Report) hit a new 52-week high of $28.24 on Apr 17. The stock delivered a one-year return of about 34.5%, while the S&P 500 gained 10.5% over the same time frame. Over the past one year, CenterPoint Energy’s share price has ranged from a low of $20.46 to a high of $28.24. Average volume of shares traded over the last three months is approximately 3 million. Factors that Back the Rise CenterPoint Energy reported positive earnings surprise in two out of the last four quarters, resulting in a positive average surprise of 0.
Spark Energy, Inc. (SPKE - Free Report) was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up 37.4% in the past one-month time frame.
Pampa Energia S.A. (PAM - Free Report) has been on the move lately as the stock has risen by 16.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET